Lu-177 DOTATATE for rare neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be a well-differentiated neuroendocrine tumor that is not in the stomach or intestines (or if it is, you must have received prior treatment more than 18 months ago).
- Your cancer must have grown or spread based on CT or MRI scans taken in the last 3 years.
- Your tumor cells must have somatostatin receptors, shown by a special scan (OctreoScan or Ga68 Dotatate PET) within the last 24 weeks.
- You must have at least one tumor that can be measured on a scan.
- You must have good kidney, liver, and blood cell counts, as checked by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
Hear when a new Paraganglioma/ Phaeochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.